Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | ADAM8 | P78325 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24263882 | 0.90 | SIRT2 (0.40) | ROCK2SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL21534077 | 0.90 | SIRT2 (0.40) | ROCK2SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL19604392 | 0.90 | SIRT2 (0.40) | ROCK2SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL21167799 | 0.89 | SIRT2 (0.44) | SIRT2SIRT1SIRT3SIRT5SPHK1 | |
| SCHEMBL19443237 | 0.88 | SIRT2 (0.43) | SIRT2SIRT1SIRT3SIRT5SPHK1 | |
| SCHEMBL25100584 | 0.88 | SIRT2 (0.43) | SIRT2SIRT1SIRT3SIRT5SPHK1 | |
| SCHEMBL20327986 | 0.88 | SIRT2 (0.43) | SIRT2SIRT1SIRT3SIRT5SPHK1 | |
| SCHEMBL20798924 | 0.87 | SIRT2 (0.41) | ROCK2SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL21784542 | 0.87 | SIRT2 (0.41) | ROCK2SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL18823531 | 0.87 | SIRT2 (0.41) | ROCK2SIRT2SIRT1SIRT3SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11596693-B2 | Antibody-drug conjugates and uses thereof | MABPLEX INTERNATIONAL CO., LTD (CN) | 2023-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596693-B2 | Antibody-drug conjugates and uses thereof | DARS1, CD2, FCGR2A | ROCK2 909/4885SIRT2 2895/4885SIRT1 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.